introduction
GZI believes in algo trading for everyone.
Enjoy a new kind of financial experience for the age of integrated asset management. GZI has executed a successful trade based on Omnicron drug research for Ascletis Pharma. We are one of the few alternative data platforms on par with leading quant funds.
Watch our investor panel with a Forbes 30 Under 30 Nominee to hear our story. Alternative sectors are the most volatile on the global public markets. Search our database to find equities with a high alternative alpha. Read our media interviews to see how we have inspired the media. Visit our app to see why crowdfunders, corporations, entrepreneurs, and wealth managers alike follow GZI.
problem
Data startups lack the financial statistics to support claims for their products.
This increases risks for customers since alternative data has no definition. GZI's alternative data is designed to translate directly to financial data.
A 2020 Statista report cites, 38% of hedge fund managers worldwide believed there would be widespread adoption for alternative data in the next three to five years. Over the last five years, returns for AI/ML, systematic and normal hedge funds were 7.6%, 5.22%, 6.03%.
Pew Research Center recently reported that roughly half of non-retired adults believe that the consequences of COVID will make it harder for them to achieve their financial goals.
solution
GZI aims to provide you with the necessary resources for you to make better, more informed investing strategies and decisions – with more accurate, timely, and granular insights that are potentially superior to global competitors.
Data startups rarely have the numbers to prove their product’s outcomes. Our platform is trained on the same data used to outperform leading robo advisors during 2020 and 2021. The AI powering alternative data makes it applicable to financial data.
success to date
- Investor panel with olympic gold medalist and Forbes 30 Under 30 Nominee Fares Ksebati
- Sits on YEC and Forbes’ Council, which is for executives under 45 with $1m in revenue or funding
- Executed a successful trade based on Omnicron drug research for Ascletis Pharma
- Returns were on par with artificial intelligence and machine learning hedge funds in 2020 and 2021.
- Works with 3 of the 4 top expert networks in the world: GLG, Guidepoint, and AlphaSights
- Recognized by the prestigious Founder Institute Accelerator as an FI Select Company – the top 3% of 6,000 companies across the globe
- Featured in Forbes with pending appearances in Inc, Rolling Stone and Newsweek
- 15 NDAs signed with brokers and investment banks
business model
market
Alternative data has the smallest market size of $4.4B and a CAGR of 54.4% within the $273.4B Big Data market growing at a CAGR of 13.4%. This makes now the optimal time for expansion. Research data and financial information have exit multiples of 40.84x EV/EBITDAR&D2 and 42.63x EV/EBIT (1-t)5, making them the highest in our sector. This makes now the optimal time for expansion.
press
GZI's media connections provide direct access to media outlets like Forbes, Inc, Rolling Stone, Newsweek, Fast Company, and Cointelegraph.
team
Use of Proceeds
If the offering's maximum amount of $524,321 is raised:
| Use | Value | % of Proceeds |
|---|---|---|
| Executive Team and Additional Members | $245,691 | 46.9% |
| Sales and Marketing | $60,000 | 11.4% |
| Product | $40,000 | 7.6% |
| Related Party Note Payable | $90,000 | 17.2% |
| Contractors | $21,000 | 4.0% |
| Office | $14,588 | 2.8% |
| Legal | $10,000 | 1.9% |
| Accounting | $7,500 | 1.4% |
| Insurance | $5,000 | 1.0% |
| Software | $4,850 | 0.9% |
| Intermediary fees | $25,692 | 4.9% |
Terms
This number includes all funds raised by the Company in this round on Netcapital. This is an offering of Class A Common Stock, under registration exemption 4(a)(6), in GZI Hub, Inc.. This offering must reach its target of at least $10,000 by its offering deadline of April 3, 2023 at 10:59pm ET. If this offering does not reach its target by the offering deadline, then your money will be refunded.
If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:
Financials
These financial statements have been reviewed by an independent Certified Public Accountant.
SEC Filings
The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.
We’re also required to share links to each of the SEC filings related to this offering with investors.
Understand the Risks
Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.
Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
More Info
Updates
- Aug 17, 2023GZI has relisted on Figure! We appreciate the...
- Jul 18, 2023GZI community: Thank you so much for all your...
- Apr 4, 2023Primary offering finalized, selling shares
- Mar 6, 2023GZI has finalized our engagement letter with...
- Feb 7, 2023Don't miss our latest appearance in YEC's...
- Feb 3, 2023GZI has been nominated as the Boldest DeFi,...
- Jan 17, 2023GZI has received an engagement letter from Nova...
- Dec 1, 2022Don't miss our Forbes panel with YEC on company...
- Dec 1, 2022GZI has relisted on Netcaptial! Read our latest...
- Feb 18, 2022Primary offering finalized, selling shares
- Feb 2, 2022Part 3/9 of our interview series with Valiant...
- Jan 26, 2022Highlights from part 2/9 of our interview...
- Nov 22, 2021Investor/Watchlist Notice: We can configure the...
- Nov 19, 2021Our domain has been transferred from gzihub.com...
- Nov 1, 2021GZI launches product updates and is presenting...
- Oct 7, 2021GZI is offering a free one month trial to...
- Oct 5, 2021GZI's website views are up 3,375% for the week.
Ask a Question
Proofread your comment before submitting: once it's posted, you can’t edit or delete it. Investors are advised to review our Discussion Board Policy before submitting a comment. For the fastest help with the web site, email help@netcapital.com instead of commenting.
Looking to raise capital?
We can help turn your friends, family and customers into investors.
Interested in more investment opportunities?
Browse all offerings currently available.